<DOC>
	<DOCNO>NCT00857259</DOCNO>
	<brief_summary>The study assess safety efficacy Everolimus ( RAD001 ) alone combination Lucentis patient neo-vascular age relate macular degeneration ( AMD )</brief_summary>
	<brief_title>The Efficacy Oral Everolimus Patients With Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients neovascular AgeRelated Macular Degeneration ( AMD ) Best correct visual acuity ( BCVA ) 20/40 bad study eye Patients predominantly classic , minimally classic , occult choroidal neovascularization macula one eye ( study eye ) inadequate response VEGF inhibitor study eye . Inadequate response define gain le one line visual acuity persistent macular edema ( central subfiel thickness ≥ 300 μm measure Optical Coherence Tomography ( OCT ) despite minimum 3 treatment Lucentis Avastin Any concurrent ocular condition study eye may result substantial change vision study Uncontrolled medical condition cancer , angina , diabetes , viral fungal infection , impaired lung function , history stroke Patients macular edema study eye , judgment investigator , unlikely respond treatment . Examples feature may guide investigator 's judgment unresponsiveness large region geographic atrophy , retinal angiomatous proliferation , large region subretinal fibrosis . The presence one feature exclude patient investigator judge study eye irreversible macular edema . active bacterial , fungal viral infection time enrollment , e.g . hepatitis B C infection . Patients risk factor hepatitis B test hepatitis B viral load serological marker screen ( positive HBVDNA , HBsAg ) . Patients risk factor hepatitis C test use HCVRNAPCR screening . A clinical history hepatitis B hepatitis C exclude patient study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>AMD</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Choroidal Neo-Vascular ( CNV ) age-onset macular degeneration</keyword>
	<keyword>Age-related Macular Degeneration ( AMD )</keyword>
</DOC>